Predicting the Impact of Monoclonal Antibodies & Vaccines on Antimicrobial Resistance

Project Information

PrIMAVeRa

Grant agreement ID: 101034420

DOI 10.3030/101034420

EC signature date 9 November 2021

Start date 1 November 2021

End date 31 October 2026

Funded under

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Total cost € 9 250 000,00

EU contribution € 6 500 000,00

Coordinated by

EUROPEAN VACCINE INITIATIVE E.V
Germany

Periodic Reporting for period 1 - PrIMAVeRa (Predicting the Impact of Monoclonal Antibodies & Vaccines on Antimicrobial Resistance)

Reporting period: 2021-11-01 to 2022-10-31

Summary of the context and overall objectives of the project

Predicting the Impact of Monoclonal Antibodies & Vaccines on Antimicrobial Resistance (PrIMAVeRA) seeks to develop mathematical models and an epidemiological repository to assess the impact of vaccines and monoclonal antibodies (mAbs) on antimicrobial resistance (AMR).

AMR causes a high burden of disease that can be reduced by preventing infections by implementing vaccines and mAb. This well-known concept is difficult to operationalize due to the high number of infections, limited resources, and the impossibility of covering an entire population. PrIMAVeRa tries to fill this gap by modeling which pathogens, infections and populations result in the highest AMR burden, and through which healthcare services priority vaccines and mAb could be delivered. The final product will be a planning tool to identify the most cost-effective vaccines and mAb strategies according to the local AMR burden.

In order to use limited resources most effectively, it is crucial to be able to rank potential interventions against AMR according to cost-effectiveness. The PrIMAVeRa project aims to provide policymakers with the comprehensive models necessary to provide this capability.

Work performed from the beginning of the project to the end of the period covered by the report and main results achieved so far

During the first project year, the Consortium focused on the literature search. Protocols for 4 systematic reviews (SR) have been developed and uploaded to the International Prospective Register of Systematic Reviews (PROSPERO): 1) frequency measures of healthcare-associated infections and antimicrobial resistance (AMR), 2) AMR-associated health outcomes, 3) AMR-associated economic outcomes 4) existing mathematical models for AMR.
In addition, a protocol for a systematic review of the grey literature was developed and registered in PROSPERO focused on obtaining individual-level data. Potential databases have been identified and database owners are being contacted for the exchange of their data.

The Consortium has selected the pathogen-infection combinations of interest, which is an important step for data gathering and model development.

The consortium management structure has been established and is in operation. PrIMAVeRa held a Workshop where AMR case studies were discussed. The consortium had a vibrant year in Communication and Dissemination, as the project website was launched (https://www.primavera-amr.eu/) multiple social media posts featuring the project were published on LinkedIn, Twitter, the project website, and other platforms. The consortium finalized the communication plan, and the Scientific Advisory Committee was established

The Consortium advanced discussions on how to make the data publicly available through the EPI-Net repository. (epi-net.eu)

Progress beyond the state of the art and expected potential impact (including the socio-economic impact and the wider societal implications of the project so far)

The outcomes of the PrIMAVeRa project are expected to generate several major impacts:

I. Faster and more effective access to relevant data: the epidemiological repository will allow access to a publicly available, searchable database on the epidemiology of a range of common bacterial infections, their associated health burden, and resource consumption for a wide range of drug-resistant as well as drug-susceptible pathogens;

II. Better capability for real-time, data-driven decision-making by policymakers and healthcare managers on vaccine and mAb strategies by utilizing well-designed mathematical models available through a user-friendly interface with country-specific information for parametrisation;

III. An innovative evidence-based approach to prioritize research and development strategies to reduce the burden of relevant AMR through vaccines and mAbs. The combination of innovative decision tools and access to real-world data may guide and thus improve the economic return of R&D in the antibacterial field, making the development of novel, effective treatments more attainable and will help fight the emergence and spread of untreatable infections.

What differentiates PrIMAVeRa from other initiatives is that the project focuses on pathogen-infection-specific impact of AMR within different patient strata, trying to distinguish the impact of gender, age, frailty and other important risk profiles to provide actionable data for prioritization of implementation of preventive strategies, like vaccines and mAbs.
rial field, making the development of novel, effective treatments more attainable and will help fight the emergence and spread of untreatable infections.

PrIMAVeRa Project Logo